Molecular structure of captopril
Find information on thousands of medical conditions and prescription drugs.

Capoten

Captopril is an Angiotensin-Converting Enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and some types of chronic heart failure. Captopril was the first ACE inhibitor developed and was considered a breakthrough both because of its novel mechanism of action and also because of the revolutionary development process. The original innovator drug Bristol-Myers Squibb's Capoten®. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Clinical Use

Development of captopril

Captopril was invented in 1975 by three researchers at the American drug company Squibb (now Bristol-Myers Squibb) , Miguel Ondetti, Bernard Rubin and David Cushman. Squibb filed for American patent protection on the drug in February 1976 and U.S. Patent was 4,046,889 was granted in September 1977.

The development of captopril was amongst the earliest successes of the revolutionary concept of structure-based drug design. The renin-angiontensin-aldosterone system had been extensively studied in the mid-20th century and it had been decided that this system presented several opportune targets in the development of novel treatments for hypertension. The first two targets that were attempted were renin and ACE. Captopril was the culmination of efforts by Squibb's laboratories to develop an ACE inhibitor.

Ondetti, Cushman and colleagues built on work that had been done in the 1960s by the British Nobel laureate Sir John Vane when he was a researcher at the Royal College of Surgeons. Working with a Brazilian colleage, SĂ©rgio Ferreira, Vane discovered a peptide in Brazilian viper venom which was a 'collected-product inhibitor' of angiotensin II. Captopril was developed from this peptide after it was found via QSAR-based modification that the terminal sulfhydryl-moiety of the peptide provided a high potency of ACE inhibition.

Capoten gained FDA approval in June 1981. The drug went generic in the U.S. in February 1996 as a result of the end of market exclusivity for Bristol-Myers Squibb.

Shortcomings

During Phase III/IV trials of captopril, it was found that captopril had some undesirable adverse effects. The most predominant of which included cough, rash and taste disturbances (metallic or loss of taste). Cough is an adverse effect common to all of the ACE inhibitors, but the rash and taste disturbances were attributed to the very sulfhydryl moiety which granted captopril its potency. An additional shortcoming of captopril is the short half-life, necessitating 2-3 times daily dosing.

The development of longer-acting ACE inhibitors lacking the sulfhydryl-moiety such as enalapril proved to be the downfall of captopril and, whilst it is still used, it is no longer amongst the more widely used ACE inhibitors.

Reference

  • Smith CG, Vane JR. The discovery of captopril. FASEB J 2003;17:788-9. Fulltext. PMID 12724335.

Read more at Wikipedia.org


[List your site here Free!]


MERCER COUNTY MAKES ITS MARK: A Rich History of Research & Development
From Mercer Business, 2/1/03

Despite Sopranos references and "What's your exit?" jokes, New Jersey is a small state with some very big advantages. Once called "America the beautiful, only smaller:" by National Geographic, New Jersey is a state rich in history, culture, entertainment and industry.

Businesses have flocked to the Garden State (especially the Mercer County region) for its central location; highly educated work force; reliable, mass transportation system; and close proximity to the financial and media resources of New York City. Some of the state's fastest growing industries - pharmaceuticals/ biotechnology, information technology, chemical and electronics - are those driven by research and development to create the new, the improved and the innovative.

"Beginning with Thomas Alva Edison, New Jersey has more inventors per square mile than any other state in the nation," says Mario Casabona, chairman of the Research & Development Council of New Jersey. In fact, New Jersey ranks fourth in total U.S. patents and has produced 30 Nobel Prize winners. "We also have the highest concentration of scientists," he notes. "As Chairman of an association that supports and promotes research and development in New Jersey, I'm proud of New Jersey's achievements and of our well-deserved reputation as The Innovation State."

New Jersey ranks first in the nation in the manufacturing of pharmaceuticals. In 2001 alone, nearly $2.4 billion was spent here for research and development of new pharmaceuticals and medical technology, and in recent years nearly 40% of all new drugs approved by the U.S. Food and Drug Administration, were created by New Jersey firms and associates. Fifteen of the largest drug companies in the world have established facilities in New Jersey, making the pharmaceutical industry the state's biggest employer.

With this rich pharmaceutical presence, it is no wonder that many important medical discoveries originated here. The anti-cancer drug, Interferon, anti-anxiety drugs such a Valium and Librium, the world's first test for Hepatitis C, antibiotics like streptomycin, Band-aid sterile bandages, Retin-A acne and wrinkle cream, Colgate's Total antibacterial toothpaste and most recently, Listerine PocketPak strips, to name just a few.

Numerous pharmaceutical breakthroughs were discovered and developed by Mercer County's Princeton-based Bristol-Myers Squibb. Among the most revolutionary are: Capoten, the first in a new class of ACE inhibitors and an important discovery in the treatment of medical discovery in the treating of hypertenstion; Videx, the second approved medicine for the treatment of HIV infection; Taxol (paclitaxel) Injection, one of the world's most widely used cancer treatments; and Pravachol for reducing the risk of heart attack in patients with elevated cholesterol or chronic heart disease.

In 1998, Bristol-Myers Squibb's Excedrin Migraine became the first migraine headache medication available to consumers without a prescription. BMS currently has a number of life-saving treatments in development for the treatment of HIV/AIDS, cancer, diabetes, hypertension, hepatitis B, rheumatoid arthritis, multiple sclerosis and other debilitating conditions.

Mercer County's Janssen Pharmaceutica Products, LP (a subsidiary of Johnson & Johnson) develops and markets prescription pharmaceuticals for use in elder care, psychiatry, gastroenterology, pain management and dermatology. Some of Janssen's breakthrough products include: Duragesic, a strong medication delivered through a transdermal patch for moderate-to-severe chronic pain; Reminyl, a treatment for patients with mild to moderate Alzheimer's disease; Aciphex, for relief of heartburn caused by erosive GERD (gastroesophageal reflux disease) and Sporanox capsules for the treatment of fungal nail infection and other mycoses.

Princeton University has also made impressive strides in pharmaceuticals and biotechnology. A Princeton University researcher discovered a multi-targeted antifolate compound to treat patients with cancer. The compound, trademarked "Alimta", is currently in Phase III clinical trials and Eli Lilly is projected to file the NDA in August 2003. Princeton University researchers also developed a technology that enables discovery and validation of novel kinase drug targets and an imaging technology that utilizes polarized inert gases to enable doctors to view soft tissue (such as the lungs) in the body using conventional MRI equipment.

Another organization in the Mercer County area, FMC, develops biopolymers for pharmaceutical applications, but the majority of their work focuses on the development of proprietary compounds in the insecticide and herbicide arena. In November 2002, Dr. George Theodoridis was awarded the Thomas Alva Edison Award by the Research & Development Council of New Jersey for the discovery and patent for sulfentrazone, an herbicide that has been commercialized around the world for the control of weeds in soybeans, sugarcane, sorghum and other crops. FMC is also a leading supplier of bindings, coatings and disintegrants in tablets for drug delivery. FMC's products in this area include Avicel PH products for tableting, Aqua-Coat functional coatings for modifying the release of drugs from tablets, colloidal Avicel for stabilization of low fat foods such as salad dressings and pharmaceutical suspensions and LusterClear, an esthetic coating for the pharmaceutical industry.

In addition to pharmaceuticals, electronics and technology are also big business in New Jersey. The state is home to 476 electronics manufacturing facilities and ranks first in the research and development of electronics innovations overall. Some of the milestone "firsts" in electronics and products that now drive the American way of life had their origin right here. The television and the electronics that made cable television possible, the photocopier, the flight simulator, the weather satellite, FM radio, and the first transistor - a part of almost every electronic device and led to the invention of the silicon gate transistor, the power behind today's computers, all came about through the ingenuity of New Jersey inventors.

In fact, one in ten New Jersey residents, who work in the private sector, is employed by a high technology firm. Beginning with Oberlin Smith, a contemporary of Thomas Alva Edison's, who back in 1877, developed a reel-toreel magnetic recording system - the technology that paved the way for the development of the tape recorder, the telephone answering machine and the computer - New Jersey has proven a leader in the high tech field.

Mercer County's Sarnoff Corporation is most widely known for developing the first color television and the color picture tube, the basis for a system that is still in use today. But Sarnoff is responsible for a number of other innovations, as well. Some of the most notable include: CMOS transistor technology, used worldwide to manufacture the vast majority of integrated circuits; the color LCD display that made the laptop computer possible; next generation advanced digital high definition television (HDTV); Amorphous Silicon Solar Cells for solar energy; the Iris Recognition personal identification system to validate users of ATMs and the world's first disposable hearing aid.

Some of New Jersey's other high tech innovations include: the high speed modem; digital cellular technology; cell phones and the batteries that power them; the laser; the laser bar code scanner; the fax machine; the semi-conductor; DSL for high speed Internet access; and the silicon germanium thermoelectric power generator that made the Voyager Space Probe possible. And then, of course, there's a little invention called "the incandescent lamp" more commonly known as the electric light.

Thomas Alva Edison, the genius who discovered electricity, made New Jersey his home and his workplace for over 40 years. Edison was granted 1,093 patents during his lifetime, more than any other inventor. In addition to the electric light and the system by which it is generated, Edison invented the dry storage battery, the electric railway, the wireless transmission of messages, the motion picture camera and, his favorite - the phonograph.

"Edison didn't just invent machines: he invented entire industries," notes Casabona.

"But perhaps the greatest invention Edison left us is the first industrial research and development laboratory: The concept of research and development as an organized process with scientific apparatus, trained assistants, and plenty of patience, imagination, creativity and hard work. This was truly the beginning of research and development. And we can proudly say it all started in New Jersey."

Copyright Mercer County Chamber of Commerce Feb 01, 2003
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Capoten
Home Contact Resources Exchange Links ebay